secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K/A
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001680367-25-000060
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement
--------------------------------------------------------------------------------

- First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.
- Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.
- Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.
- Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/0001680367-25-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/sttk-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001680367-25-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer